MIRNA-503-5P inhibitor
MIRNA-503-5P inhibitor has been studied in 1 paper since 2022: none in people yet, 1 in animals. The research so far is in animals. The newest paper, May 13, 2022: “MicroRNA Expression Profiling in Age-Dependent Renal Impairment”.
1 paper studies it3 findingsUpdated
See all 1 papers on MIRNA-503-5P inhibitor
At a glance
The findings reach mice, none yet in people. 1 lab in 1 country.
None of its findings points the other way.
- 1 lab in 1 country
- Funder: Japan Society for the Promotion of Science
- Animals1
What did studies of MIRNA-503-5P inhibitor find?
3Studies of MIRNA-503-5P inhibitor measured 3 outcomes: age-dependent renal impairment, glomerulosclerosis and renal fibrosis.
Age-dependent renal impairment
no changein mice1
1 study
Age-dependent renal impairment
no changein mice1
MIRNA-503-5P inhibitor showed no clear effect on age-dependent renal impairment in SAMP1 mice.
Animalsin SAMP1 micePEI-NPs5 nmol
Glomerulosclerosis
downin mice1
1 study
Glomerulosclerosis
downin mice1
MIRNA-503-5P inhibitor decreases glomerulosclerosis in mice (administered with PEI-NPs in SAMP1 mice).
Animalsadministered with PEI-NPs in SAMP1 micePEI-NPskidney5 nmol
Renal fibrosis
downin mice1
1 study
Renal fibrosis
downin mice1
MIRNA-503-5P inhibitor decreases renal fibrosis in mice (administered with PEI-NPs in SAMP1 mice).
Animalsadministered with PEI-NPs in SAMP1 micePEI-NPskidney5 nmol